查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1452675

全球恶性间皮瘤市场 - 全球产业分析、规模、占有率、成长、趋势、预测 (2031) - 依药物类型、依给药途径、依分销管道、依地区

Malignant Mesothelioma Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
出版日期: | 出版商: Fairfield Market Research | 英文 223 Pages | 商品交期: 2-5个工作天内

价格
简介目录

全球恶性间皮瘤市场正经历典范转移，培美曲塞和联合治疗领域正成为彻底改变治疗方法的领导者。 预计到预测期结束时，该细分市场将占大部分市场，收入占有率将超过 45%。 由于出色的反应率和对联合治疗的日益关注，该领域的复合年增长率 (CAGR) 高达 7.4%，预计将突破 3 亿美元。

培美曲塞已被确立为恶性间皮瘤治疗的基石，因为它作为单一疗法和与其他药物联合疗法均显示出显着的疗效。 临床试验表明，与培美曲塞联合使用时的缓解率为30%至40%，为市场占有率的大幅增加铺平了道路。 公司正在加紧努力以获得新的联合治疗方案的批准，这些方案利用不同药物的协同作用来改善患者的治疗效果。

合作研究已成为业界参与者探索联合疗法治疗恶性间皮瘤潜力的重要策略。 拥有程序专利的公司数量有限，引发了专注于不同药物组合的合作研究计划。 特别是，Boehringer Ingelheim的尼达尼布联合培美曲塞/顺铂的 3 期试验体现了为增加治疗选择和拓宽治疗前景而共同努力的结果。

本报告调查了全球恶性间皮瘤市场，并提供了市场概况、药物类型趋势、给药途径、分销管道、区域以及进入市场的公司的竞争趋势。它提供了。

目录

第 1 章执行摘要

第二章市场概述

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影响分析
  • 乌克兰和俄罗斯之间衝突的影响
  • 经济概况
  • 杵分析

第三章2018-2031年全球恶性间皮瘤市场前景

  • 2018-2031 年全球恶性间皮瘤市场前景（依药物类型、价值（十亿美元））
  • 2018-2031 年全球恶性间皮瘤市场前景（依给药途径）、价值（十亿美元）
  • 2018-2031 年全球恶性间皮瘤市场前景（依分销管道）、价值（十亿美元）
  • 2018-2031 年全球恶性间皮瘤市场前景（依地区、价值（十亿美元））

第四章北美恶性间皮瘤市场前景，2018-2031

第五章欧洲恶性间皮瘤市场前景，2018-2031

第 6 章亚太地区恶性间皮瘤市场展望，2018-2031

第 7 章拉丁美洲恶性间皮瘤市场展望，2018-2031

第8章中东与非洲恶性间皮瘤市场前景，2018-2031

第九章竞争态势

  • 依药物类型和给药途径划分的热图
  • 2023 年公司市占率分析
  • 竞争力仪表板
  • 公司简介
    • AstraZeneca Plc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Eli Lilly and Company
    • Teva Pharmaceuticals
    • Boehringer Ingelheim GmbH
    • Mylan N.V.
    • Fresenius Kabi AG
    • Sun Pharmaceuticals Industries Ltd
    • Corden Pharma International GmbH
    • Concordia International Corp

第 10 章附录

简介目录

The global malignant mesothelioma market is witnessing a paradigm shift, with the Pemetrexed and combination therapy segment emerging as the frontrunner in revolutionizing treatment approaches. According to comprehensive market analysis, this segment is anticipated to capture a significant portion of the market, accounting for over 45% revenue share by the end of the forecast period. With an impressive compound annual growth rate (CAGR) of 7.4%, the segment is poised to exceed US$ 300 million, driven by its superior response rates and increasing focus on combination therapies.

Enhanced Efficacy Fuels Growth

The remarkable efficacy demonstrated by Pemetrexed, either as a standalone therapy or in combination with other drugs, underscores its position as the cornerstone of malignant mesothelioma treatment. Clinical studies have revealed response rates ranging from 30% to 40% when Pemetrexed is used in combination, paving the way for a significant expansion in market share. Companies are intensifying efforts to secure approvals for novel combination therapy regimens, leveraging the synergistic effects of different drugs to enhance patient outcomes.

Collaborative Research Drives Innovation

Collaboration has emerged as a key strategy among industry players to explore the potential of combination therapies in malignant mesothelioma treatment. With a limited number of companies holding patents for procedures, collaborative research initiatives have gained traction, focusing on diverse combinations of drugs. Notably, Boehringer Ingelheim's phase 3 study of Nintedanib in combination with Pemetrexed/Cisplatin exemplifies the concerted efforts towards advancing treatment options and expanding the therapeutic landscape.

Rising Incidence Promotes Market Growth

Contrary to assumptions based on asbestos restrictions, the incidence of malignant mesothelioma continues to rise, particularly among men. Statistics released by Cancer Research UK highlight a concerning trend, with 1 in every 140 men and 1 in every 710 women diagnosed with the disease. This demographic shift underscores the urgent need for effective therapeutic interventions, propelling the demand for Pemetrexed and combination therapies.

Exploring Combination Therapies

The evolution of combination therapies represents a pivotal advancement in the management of malignant mesothelioma, offering a multifaceted approach to tumor regulation. By targeting multiple pathways involved in tumor progression, combination therapies hold promise in significantly improving survival rates. Various modalities, including chemotherapy combined with radiotherapy, targeted antibodies, cryotherapy, and immunotherapies, are poised to expand the potential indications for existing drugs, providing hope for patients and clinicians alike.

Regional Dynamics

While the global market for malignant mesothelioma is poised for substantial growth, regional variations in market dynamics are evident. The Asia Pacific, Latin America, and Middle East & Africa regions are projected to witness the highest CAGRs for the Pemetrexed and combination therapy segment. With a market attractiveness index of 2.7, Latin America emerges as a particularly promising market, reflecting the growing acceptance and adoption of innovative treatment modalities.

Key Companies

  • AstraZeneca Plc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Eli Lilly and Company
  • Teva Pharmaceuticals
  • Boehringer Ingelheim GmbH
  • Mylan N.V.
  • Fresenius Kabi AG
  • Sun Pharmaceuticals Industries Ltd
  • Corden Pharma International GmbH
  • Concordia International Corp
  • Kyowa Hakko Kirin Co Ltd.
  • Polaris Pharmaceuticals, Inc.
  • MolMed SpA
  • Ono Pharmaceutical Co. Ltd
  • Nichi-Iko Pharmaceutical Co., Ltd
  • Others.

Market Segmentation:

Drug Type

  • Pemetrexed
  • Cisplatin
  • Carboplatin
  • Gemcitabine
  • Vinorelbine
  • Others

Route of Administration

  • Oral
  • Parenteral

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Oncology Centers

Region

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA

Table of Contents

1. Executive Summary

  • 1.1. Global Malignant Mesothelioma Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Malignant Mesothelioma Market Outlook, 2018 - 2031

  • 3.1. Global Malignant Mesothelioma Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Pemetrexed
      • 3.1.1.2. Cisplatin
      • 3.1.1.3. Carboplatin
      • 3.1.1.4. Gemcitabine
      • 3.1.1.5. Vinorelbine
      • 3.1.1.6. Others
  • 3.2. Global Malignant Mesothelioma Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Oral
      • 3.2.1.2. Parenteral
  • 3.3. Global Malignant Mesothelioma Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Hospital Pharmacies
      • 3.3.1.2. Retail Pharmacies
      • 3.3.1.3. Oncology Centres
  • 3.4. Global Malignant Mesothelioma Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Malignant Mesothelioma Market Outlook, 2018 - 2031

  • 4.1. North America Malignant Mesothelioma Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Pemetrexed
      • 4.1.1.2. Cisplatin
      • 4.1.1.3. Carboplatin
      • 4.1.1.4. Gemcitabine
      • 4.1.1.5. Vinorelbine
      • 4.1.1.6. Others
  • 4.2. North America Malignant Mesothelioma Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Oral
      • 4.2.1.2. Parenteral
  • 4.3. North America Malignant Mesothelioma Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Hospital Pharmacies
      • 4.3.1.2. Retail Pharmacies
      • 4.3.1.3. Oncology Centres
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis
  • 4.4. North America Malignant Mesothelioma Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.2. U.S. Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 4.4.1.3. U.S. Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.4.1.4. Canada Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.5. Canada Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 4.4.1.6. Canada Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Malignant Mesothelioma Market Outlook, 2018 - 2031

  • 5.1. Europe Malignant Mesothelioma Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Pemetrexed
      • 5.1.1.2. Cisplatin
      • 5.1.1.3. Carboplatin
      • 5.1.1.4. Gemcitabine
      • 5.1.1.5. Vinorelbine
      • 5.1.1.6. Others
  • 5.2. Europe Malignant Mesothelioma Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Oral
      • 5.2.1.2. Parenteral
  • 5.3. Europe Malignant Mesothelioma Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospital Pharmacies
      • 5.3.1.2. Retail Pharmacies
      • 5.3.1.3. Oncology Centres
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Malignant Mesothelioma Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.2. Germany Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.4.1.3. Germany Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.4. U.K. Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.5. U.K. Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.4.1.6. U.K. Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.7. France Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.8. France Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.4.1.9. France Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.10. Italy Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.11. Italy Malignant Mesothelioma Market by Route of Administration,Value (US$Bn), 2018 - 2031
      • 5.4.1.12. Italy Malignant Mesothelioma Market by Distribution Channel, Value(US$Bn), 2018 - 2031
      • 5.4.1.13. Turkey Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.14. Turkey Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.4.1.15. Turkey Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.16. Russia Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.17. Russia Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.4.1.18. Russia Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Malignant Mesothelioma Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Malignant Mesothelioma Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Pemetrexed
      • 6.1.1.2. Cisplatin
      • 6.1.1.3. Carboplatin
      • 6.1.1.4. Gemcitabine
      • 6.1.1.5. Vinorelbine
      • 6.1.1.6. Others
  • 6.2. Asia Pacific Malignant Mesothelioma Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Oral
      • 6.2.1.2. Parenteral
  • 6.3. Asia Pacific Malignant Mesothelioma Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospital Pharmacies
      • 6.3.1.2. Retail Pharmacies
      • 6.3.1.3. Oncology Centres
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Malignant Mesothelioma Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.2. China Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.4.1.3. China Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.4. Japan Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.5. Japan Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.4.1.6. Japan Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.7. South Korea Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.8. South Korea Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.4.1.9. South Korea Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.10. India Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.11. India Malignant Mesothelioma Market by Route of Administration,Value (US$Bn), 2018 - 2031
      • 6.4.1.12. India Malignant Mesothelioma Market by Distribution Channel, Value(US$Bn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Malignant Mesothelioma Market Outlook, 2018 - 2031

  • 7.1. Latin America Malignant Mesothelioma Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Pemetrexed
      • 7.1.1.2. Cisplatin
      • 7.1.1.3. Carboplatin
      • 7.1.1.4. Gemcitabine
      • 7.1.1.5. Vinorelbine
      • 7.1.1.6. Others
  • 7.2. Latin America Malignant Mesothelioma Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Oral
      • 7.2.1.2. Parenteral
  • 7.3. Latin America Malignant Mesothelioma Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospital Pharmacies
      • 7.3.1.2. Retail Pharmacies
      • 7.3.1.3. Oncology Centres
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Malignant Mesothelioma Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.2. Brazil Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.4.1.3. Brazil Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.4. Mexico Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.5. Mexico Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.4.1.6. Mexico Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.7. Argentina Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.8. Argentina Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.4.1.9. Argentina Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Malignant Mesothelioma Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Malignant Mesothelioma Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Pemetrexed
      • 8.1.1.2. Cisplatin
      • 8.1.1.3. Carboplatin
      • 8.1.1.4. Gemcitabine
      • 8.1.1.5. Vinorelbine
      • 8.1.1.6. Others
  • 8.2. Middle East & Africa Malignant Mesothelioma Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Oral
      • 8.2.1.2. Parenteral
  • 8.3. Middle East & Africa Malignant Mesothelioma Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospital Pharmacies
      • 8.3.1.2. Retail Pharmacies
      • 8.3.1.3. Oncology Centres
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Malignant Mesothelioma Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.2. GCC Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.4.1.3. GCC Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.4. South Africa Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.5. South Africa Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.4.1.6. South Africa Malignant Mesothelioma Market by Distribution Channel,Value (US$Bn), 2018 - 2031
      • 8.4.1.7. Egypt Malignant Mesothelioma Market by Drug Type, Value (US$Bn), 2018 - 2031
      • 8.4.1.8. Egypt Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.4.1.9. Egypt Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.10. Nigeria Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.11. Nigeria Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.4.1.12. Nigeria Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Drug Type vs by Route of Administration Heat map
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. AstraZeneca Plc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Bristol-Myers Squibb Company
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. F. Hoffmann-La Roche Ltd.
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Merck & Co., Inc.
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Novartis AG
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Pfizer Inc.
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Sanofi
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Eli Lilly and Company
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Teva Pharmaceuticals
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Boehringer Ingelheim GmbH
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development
    • 9.4.11. Mylan N.V.
      • 9.4.11.1. Company Overview
      • 9.4.11.2. Product Portfolio
      • 9.4.11.3. Financial Overview
      • 9.4.11.4. Business Strategies and Development
    • 9.4.12. Fresenius Kabi AG
      • 9.4.12.1. Company Overview
      • 9.4.12.2. Product Portfolio
      • 9.4.12.3. Financial Overview
      • 9.4.12.4. Business Strategies and Development
    • 9.4.13. Sun Pharmaceuticals Industries Ltd
      • 9.4.13.1. Company Overview
      • 9.4.13.2. Product Portfolio
      • 9.4.13.3. Financial Overview
      • 9.4.13.4. Business Strategies and Development
    • 9.4.14. Corden Pharma International GmbH
      • 9.4.14.1. Company Overview
      • 9.4.14.2. Product Portfolio
      • 9.4.14.3. Financial Overview
      • 9.4.14.4. Business Strategies and Development
    • 9.4.15. Concordia International Corp
      • 9.4.15.1. Company Overview
      • 9.4.15.2. Product Portfolio
      • 9.4.15.3. Financial Overview
      • 9.4.15.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations

List of Region/Countries

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Turkey
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa